Bio Farma Boss Is Optimistic That He Can Capai The Production Target Of 20 Million Doses Of IndoVac Vaccine

President Director of Bio Farma, Honesti Basyir. (Photo: Doc. Antara)

JAKARTA - PT Bio Farma (Persero) targets 20 million doses of IndoVac Vaccine production by the end of 2022.

The number of production of the COVID-19 BUMN vaccine has only reached 1.7 million doses.

Meanwhile, of the total 1.7 million doses, only 300,000 doses were released by the Food and Drug Supervisory Agency (BPOM).

President Director of Bio Farma, Honesti Basyir ensures that his party will continue to increase the number of IndoVac vaccine production so that it can reach 20 million doses, according to the government's target by the end of this year.

"What we have now is produced, yes, 1.7 million doses, this has been released with only 300,000 BPOM, so there are still processed," Honesti said, quoted on Thursday, October 27.

Honesti said that the 20 million doses of BUMN vaccine produced per year were based on the needs or requests of the government.

Meanwhile, the capacity or ability to produce the IndoVac vaccine reaches 120 million doses per year.

This means that the holding company for Pharmaceutical SOEs does not have the limitations to produce vaccines, in fact the company is able to produce more SOE vaccines.

"Actually, our production capacity is very large, so as long as the domestic needs are still high from the government, we actually have a production capacity of up to 120 million doses per year, so it's very large," he said.

However, Honesti continued, Bio Farma will only produce BUMN vaccines based on government demand and needs.

"But this will continue to increase, so we just wait for the government's needs from the IndoVac Vaccine, later we will prepare the production capacity. Overall there are no issues with capacity, because our capacity is very high," he said.